Haleon's UK Nexium Extension Sates Appetite For Larger Pack Size
Executive Summary
The launch of a larger pack size for Nexium Control offers frequent heartburn sufferers “improved value at a lower cost per tablet, and a second course of medication on hand should their symptoms reoccur at a later date,” says Haleon.
You may also be interested in...
UK Pharmacies Recommending Short-Term Treatments Over PPIs For Frequent Heartburn – Haleon Survey
Haleon data shows a notable increase in UK pharmacy teams recommending PPIs for frequent heartburn in the year ended September 2022. However, pharmacies are still recommending alginate-based OTCs and antacids over PPIs for frequent heartburn in the majority of occasions, which Haleon says points to a need for more pharmacy education.
GSK's OTC Nexium Commercial In UK Didn't Encourage Inappropriate Use, Ad Watchdog Says
UK TV commercial for GSK's Nexium Control acid reflux treatment investigated by Advertising Standards Authority after complaint alleged promotion was irresponsible and potentially harmful. ASA found no wrongdoing by GSK and judged firm didn't breach UK Code of Broadcast Advertising.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.